Direct Oral Anticoagulants (DOACs) Device Global Market Report 2025

Description

Direct oral anticoagulant (DOAC) devices are medical instruments or diagnostic tools designed to monitor and manage the blood-thinning effects of direct oral anticoagulant medications. These devices enable clinicians to assess anticoagulation status and drug levels in patients taking medications such as rivaroxaban, apixaban, edoxaban, or dabigatran, ensuring safe and effective therapy.

The primary products of DOAC devices include factor Xa inhibitors and direct thrombin inhibitors. Factor Xa inhibitors are anticoagulant medications that selectively block the activity of factor Xa, a key enzyme in the blood coagulation cascade, preventing the formation of harmful blood clots. They are commonly used to manage conditions such as atrial fibrillation, deep vein thrombosis, pulmonary embolism, heart attacks, and post-surgical thromboprophylaxis. Their applications cover stroke prevention, venous thromboembolism prevention, treatment of acute thrombotic events, long-term prophylaxis, and more. These devices are utilized by hospitals, ambulatory surgical centers, specialty clinics, homecare settings, and other healthcare providers.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The fast surge in U.S. tariffs and the trade tensions that followed in spring 2025 are heavily affecting the medical equipment sector, particularly for imported imaging machine components, surgical-grade stainless steel, and plastic disposables. Hospitals and clinics resist price hikes, pressuring manufacturers' margins. Regulatory hurdles compound the problem, as tariff-related supplier changes often require re-certification of devices, delaying time-to-market. Companies are mitigating risks by dual-sourcing critical parts, expanding domestic production of commoditized items, and accelerating R&D in cost-efficient materials.

The direct oral anticoagulants (DOACs) device market research report is one of a series of new reports from The Business Research Company that provides direct oral anticoagulants (DOACs) device market statistics, including direct oral anticoagulants (DOACs) device industry global market size, regional shares, competitors with a direct oral anticoagulants (DOACs) device market share, detailed direct oral anticoagulants (DOACs) device market segments, market trends and opportunities, and any further data you may need to thrive in the direct oral anticoagulants (DOACs) device industry. This direct oral anticoagulants (DOACs) device market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The direct oral anticoagulants (DOACs) device market size has grown strongly in recent years. It will grow from $30.10 billion in 2024 to $32.80 billion in 2025 at a compound annual growth rate (CAGR) of 9.0%. The growth in the historic period can be attributed to the rising prevalence of cardiovascular disorders, increasing incidence of atrial fibrillation, growing awareness of stroke prevention, rising anticoagulant prescriptions, and the expanding geriatric population.

The direct oral anticoagulants (DOACs) device market size is expected to see strong growth in the next few years. It will grow to $45.65 billion in 2029 at a compound annual growth rate (CAGR) of 8.6%. The growth in the forecast period can be attributed to increasing adoption of personalized medicine, rising preference for home-based anticoagulant management, growing demand for rapid diagnostic tools, expanding awareness of stroke prevention, and development of healthcare infrastructure in emerging markets. Major trends during this period include integration of smart sensors into monitoring devices, development of point-of-care direct oral anticoagulant testing tools, continuous innovation in drug delivery systems, incorporation into routine clinical workflows, and advancements in patient compliance technologies.

The rising prevalence of cardiovascular disorders is expected to drive the growth of the direct oral anticoagulants (DOACs) device market going forward. Cardiovascular disorders encompass conditions that affect the heart and blood vessels, often causing heart attacks, strokes, or other circulatory complications. The increase in these disorders is driven by increasingly sedentary lifestyles, which contribute to weight gain, high blood pressure, and weakened cardiovascular function over time. Direct oral anticoagulants (DOACs) help manage cardiovascular conditions by reducing the risk of stroke and blood clots in patients with atrial fibrillation, providing effective anticoagulation without frequent blood monitoring. For example, in January 2025, the American Heart Association, a US-based nonprofit organization, reported that cardiovascular disease caused 941,652 deaths in the US in 2022, an increase from 931,578 deaths in 2021. Therefore, the growing prevalence of cardiovascular disorders is fueling the growth of the direct oral anticoagulants (DOACs) device market.

Companies in the direct oral anticoagulants (DOACs) device market are developing advanced solutions, such as automated coagulation assays, to enhance the accuracy, efficiency, and consistency of anticoagulant monitoring in clinical laboratories. Automated coagulation assays are laboratory tests performed by machines to measure blood clotting speed, aiding in the diagnosis of bleeding or clotting disorders. For instance, in February 2024, Roche Holding AG, a Switzerland-based pharmaceutical company, launched three coagulation tests designed specifically for Factor Xa inhibitors. These tests allow clinicians to accurately assess the anticoagulation status of patients taking rivaroxaban, apixaban, edoxaban, and heparin, supporting critical decisions during bleeding events, overdoses, or urgent surgeries. Using Roche's reagent cassette technology on cobas t analyzers, these automated assays deliver reliable results, reduce manual handling, and optimize laboratory workflow efficiency.

In July 2024, Perosphere Technologies Inc., a US-based medical diagnostics company, partnered with CoRRect Medical to exclusively distribute its reagent-free point-of-care coagulometer in Germany. This partnership aims to meet unmet needs in coagulation testing by enabling rapid bedside assessment of anticoagulation status, particularly for patients on direct oral anticoagulants, improving treatment decisions, patient outcomes, and reducing healthcare costs. CoRRect Medical is a Germany-based medical device company.

Major players in the direct oral anticoagulants (DOACs) device market are Pfizer Inc., Roche Diagnostics Corporation, Bristol-Myers Squibb Company, Siemens Healthcare GmbH, Becton Dickinson And Company, Boehringer Ingelheim International GmbH, Teva Pharmaceutical Industries Limited, Daiichi Sankyo Co. Ltd, Sysmex Corporation, Dr. Reddy's Laboratories Limited, Werfen S.A., Alembic Pharmaceuticals Limited, Diagnostica Stago SAS, Helena Laboratories Corporation, iLine Microsystems S.L., Technoclone GmbH, Anthos Therapeutics Inc., FLoBio LLC, Perosphere Technologies Inc., and DOASENSE GmbH.

North America was the largest region in the direct oral anticoagulants (DOACs) device market in 2024. The regions covered in direct oral anticoagulants (DOACs) device market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the direct oral anticoagulants (DOACs) device market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The direct oral anticoagulants (DOACs) device market consists of sales of drug delivery devices, monitoring devices, adherence management tools and digital health platforms. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Direct Oral Anticoagulants (DOACs) Device Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on direct oral anticoagulants (doacs) device market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, post-pandemic supply chain realignment, inflation and interest rate fluctuations, and evolving regulatory landscapes.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for direct oral anticoagulants (doacs) device ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The direct oral anticoagulants (doacs) device market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The market characteristics section of the report defines and explains the market.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.

Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

Markets Covered:1) By Product: Factor Xa Inhibitors; Direct Thrombin Inhibitors
2) By Disease: Atrial Fibrillation; Deep Vein Thrombosis; Pulmonary Embolism; Heart Attacks; Post-Surgical Thromboprophylaxis; Other Diseases
3) By Application: Stroke Prevention; Venous Thromboembolism Prevention; Treatment Of Acute Thrombotic Events; Long-Term Prophylaxis; Other Applications
4) By End User: Hospitals; Ambulatory Surgical Centers; Specialty Clinics; Homecare Settings; Other End Users
Subsegments:
1) By Factor Xa Inhibitors: Rivaroxaban Monitoring Devices; Apixaban Monitoring Devices; Edoxaban Monitoring Devices; Betrixaban Monitoring Devices
2) By Direct Thrombin Inhibitors: Dabigatran Etexilate; Dabigatran Mesylate
Companies Mentioned: Pfizer Inc.; Roche Diagnostics Corporation; Bristol-Myers Squibb Company; Siemens Healthcare GmbH; Becton Dickinson And Company; Boehringer Ingelheim International GmbH; Teva Pharmaceutical Industries Limited; Daiichi Sankyo Co. Ltd; Sysmex Corporation; Dr. Reddy's Laboratories Limited; Werfen S.A.; Alembic Pharmaceuticals Limited; Diagnostica Stago SAS; Helena Laboratories Corporation; iLine Microsystems S.L.; Technoclone GmbH; Anthos Therapeutics Inc.; FLoBio LLC; Perosphere Technologies Inc.; DOASENSE GmbH.
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: PDF, Word and Excel Data Dashboard.

Product Code: r37752

1. Executive Summary

2. Direct Oral Anticoagulants (DOACs) Device Market Characteristics

3. Direct Oral Anticoagulants (DOACs) Device Market Trends And Strategies

4. Direct Oral Anticoagulants (DOACs) Device Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

4.1. Supply Chain Impact from Tariff War & Trade Protectionism

5. Global Direct Oral Anticoagulants (DOACs) Device Growth Analysis And Strategic Analysis Framework

5.1. Global Direct Oral Anticoagulants (DOACs) Device PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
5.2. Analysis Of End Use Industries
5.3. Global Direct Oral Anticoagulants (DOACs) Device Market Growth Rate Analysis
5.4. Global Direct Oral Anticoagulants (DOACs) Device Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
5.5. Global Direct Oral Anticoagulants (DOACs) Device Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
5.6. Global Direct Oral Anticoagulants (DOACs) Device Total Addressable Market (TAM)

6. Direct Oral Anticoagulants (DOACs) Device Market Segmentation

6.1. Global Direct Oral Anticoagulants (DOACs) Device Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Factor Xa Inhibitors
Direct Thrombin Inhibitors
6.2. Global Direct Oral Anticoagulants (DOACs) Device Market, Segmentation By Disease , Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Atrial Fibrillation
Deep Vein Thrombosis
Pulmonary Embolism
Heart Attacks
Post-Surgical Thromboprophylaxis
Other Diseases
6.3. Global Direct Oral Anticoagulants (DOACs) Device Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Stroke Prevention
Venous Thromboembolism Prevention
Treatment Of Acute Thrombotic Events
Long-Term Prophylaxis
Other Applications
6.4. Global Direct Oral Anticoagulants (DOACs) Device Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Hospitals
Ambulatory Surgical Centers
Specialty Clinics
Homecare Settings
Other End Users
6.5. Global Direct Oral Anticoagulants (DOACs) Device Market, Sub-Segmentation Of Factor Xa Inhibitors, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Rivaroxaban Monitoring Devices
Apixaban Monitoring Devices
Edoxaban Monitoring Devices
Betrixaban Monitoring Devices
6.6. Global Direct Oral Anticoagulants (DOACs) Device Market, Sub-Segmentation Of Direct Thrombin Inhibitors, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Dabigatran Etexilate
Dabigatran Mesylate

7. Direct Oral Anticoagulants (DOACs) Device Market Regional And Country Analysis

7.1. Global Direct Oral Anticoagulants (DOACs) Device Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
7.2. Global Direct Oral Anticoagulants (DOACs) Device Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Direct Oral Anticoagulants (DOACs) Device Market

8.1. Asia-Pacific Direct Oral Anticoagulants (DOACs) Device Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
8.2. Asia-Pacific Direct Oral Anticoagulants (DOACs) Device Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.3. Asia-Pacific Direct Oral Anticoagulants (DOACs) Device Market, Segmentation By Disease , Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.4. Asia-Pacific Direct Oral Anticoagulants (DOACs) Device Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Direct Oral Anticoagulants (DOACs) Device Market

9.1. China Direct Oral Anticoagulants (DOACs) Device Market Overview
9.2. China Direct Oral Anticoagulants (DOACs) Device Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.3. China Direct Oral Anticoagulants (DOACs) Device Market, Segmentation By Disease , Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.4. China Direct Oral Anticoagulants (DOACs) Device Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Direct Oral Anticoagulants (DOACs) Device Market

10.1. India Direct Oral Anticoagulants (DOACs) Device Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.2. India Direct Oral Anticoagulants (DOACs) Device Market, Segmentation By Disease , Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.3. India Direct Oral Anticoagulants (DOACs) Device Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Direct Oral Anticoagulants (DOACs) Device Market

11.1. Japan Direct Oral Anticoagulants (DOACs) Device Market Overview
11.2. Japan Direct Oral Anticoagulants (DOACs) Device Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.3. Japan Direct Oral Anticoagulants (DOACs) Device Market, Segmentation By Disease , Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.4. Japan Direct Oral Anticoagulants (DOACs) Device Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Direct Oral Anticoagulants (DOACs) Device Market

12.1. Australia Direct Oral Anticoagulants (DOACs) Device Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.2. Australia Direct Oral Anticoagulants (DOACs) Device Market, Segmentation By Disease , Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.3. Australia Direct Oral Anticoagulants (DOACs) Device Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Direct Oral Anticoagulants (DOACs) Device Market

13.1. Indonesia Direct Oral Anticoagulants (DOACs) Device Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.2. Indonesia Direct Oral Anticoagulants (DOACs) Device Market, Segmentation By Disease , Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.3. Indonesia Direct Oral Anticoagulants (DOACs) Device Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Direct Oral Anticoagulants (DOACs) Device Market

14.1. South Korea Direct Oral Anticoagulants (DOACs) Device Market Overview
14.2. South Korea Direct Oral Anticoagulants (DOACs) Device Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.3. South Korea Direct Oral Anticoagulants (DOACs) Device Market, Segmentation By Disease , Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.4. South Korea Direct Oral Anticoagulants (DOACs) Device Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Direct Oral Anticoagulants (DOACs) Device Market

15.1. Western Europe Direct Oral Anticoagulants (DOACs) Device Market Overview
15.2. Western Europe Direct Oral Anticoagulants (DOACs) Device Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.3. Western Europe Direct Oral Anticoagulants (DOACs) Device Market, Segmentation By Disease , Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.4. Western Europe Direct Oral Anticoagulants (DOACs) Device Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Direct Oral Anticoagulants (DOACs) Device Market

16.1. UK Direct Oral Anticoagulants (DOACs) Device Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.2. UK Direct Oral Anticoagulants (DOACs) Device Market, Segmentation By Disease , Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.3. UK Direct Oral Anticoagulants (DOACs) Device Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Direct Oral Anticoagulants (DOACs) Device Market

17.1. Germany Direct Oral Anticoagulants (DOACs) Device Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.2. Germany Direct Oral Anticoagulants (DOACs) Device Market, Segmentation By Disease , Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.3. Germany Direct Oral Anticoagulants (DOACs) Device Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Direct Oral Anticoagulants (DOACs) Device Market

18.1. France Direct Oral Anticoagulants (DOACs) Device Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.2. France Direct Oral Anticoagulants (DOACs) Device Market, Segmentation By Disease , Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.3. France Direct Oral Anticoagulants (DOACs) Device Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Direct Oral Anticoagulants (DOACs) Device Market

19.1. Italy Direct Oral Anticoagulants (DOACs) Device Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.2. Italy Direct Oral Anticoagulants (DOACs) Device Market, Segmentation By Disease , Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.3. Italy Direct Oral Anticoagulants (DOACs) Device Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Direct Oral Anticoagulants (DOACs) Device Market

20.1. Spain Direct Oral Anticoagulants (DOACs) Device Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.2. Spain Direct Oral Anticoagulants (DOACs) Device Market, Segmentation By Disease , Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.3. Spain Direct Oral Anticoagulants (DOACs) Device Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Direct Oral Anticoagulants (DOACs) Device Market

21.1. Eastern Europe Direct Oral Anticoagulants (DOACs) Device Market Overview
21.2. Eastern Europe Direct Oral Anticoagulants (DOACs) Device Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.3. Eastern Europe Direct Oral Anticoagulants (DOACs) Device Market, Segmentation By Disease , Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.4. Eastern Europe Direct Oral Anticoagulants (DOACs) Device Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Direct Oral Anticoagulants (DOACs) Device Market

22.1. Russia Direct Oral Anticoagulants (DOACs) Device Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.2. Russia Direct Oral Anticoagulants (DOACs) Device Market, Segmentation By Disease , Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.3. Russia Direct Oral Anticoagulants (DOACs) Device Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Direct Oral Anticoagulants (DOACs) Device Market

23.1. North America Direct Oral Anticoagulants (DOACs) Device Market Overview
23.2. North America Direct Oral Anticoagulants (DOACs) Device Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.3. North America Direct Oral Anticoagulants (DOACs) Device Market, Segmentation By Disease , Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.4. North America Direct Oral Anticoagulants (DOACs) Device Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Direct Oral Anticoagulants (DOACs) Device Market

24.1. USA Direct Oral Anticoagulants (DOACs) Device Market Overview
24.2. USA Direct Oral Anticoagulants (DOACs) Device Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.3. USA Direct Oral Anticoagulants (DOACs) Device Market, Segmentation By Disease , Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.4. USA Direct Oral Anticoagulants (DOACs) Device Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Direct Oral Anticoagulants (DOACs) Device Market

25.1. Canada Direct Oral Anticoagulants (DOACs) Device Market Overview
25.2. Canada Direct Oral Anticoagulants (DOACs) Device Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.3. Canada Direct Oral Anticoagulants (DOACs) Device Market, Segmentation By Disease , Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.4. Canada Direct Oral Anticoagulants (DOACs) Device Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Direct Oral Anticoagulants (DOACs) Device Market

26.1. South America Direct Oral Anticoagulants (DOACs) Device Market Overview
26.2. South America Direct Oral Anticoagulants (DOACs) Device Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.3. South America Direct Oral Anticoagulants (DOACs) Device Market, Segmentation By Disease , Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.4. South America Direct Oral Anticoagulants (DOACs) Device Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Direct Oral Anticoagulants (DOACs) Device Market

27.1. Brazil Direct Oral Anticoagulants (DOACs) Device Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.2. Brazil Direct Oral Anticoagulants (DOACs) Device Market, Segmentation By Disease , Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.3. Brazil Direct Oral Anticoagulants (DOACs) Device Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Direct Oral Anticoagulants (DOACs) Device Market

28.1. Middle East Direct Oral Anticoagulants (DOACs) Device Market Overview
28.2. Middle East Direct Oral Anticoagulants (DOACs) Device Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.3. Middle East Direct Oral Anticoagulants (DOACs) Device Market, Segmentation By Disease , Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.4. Middle East Direct Oral Anticoagulants (DOACs) Device Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Direct Oral Anticoagulants (DOACs) Device Market

29.1. Africa Direct Oral Anticoagulants (DOACs) Device Market Overview
29.2. Africa Direct Oral Anticoagulants (DOACs) Device Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.3. Africa Direct Oral Anticoagulants (DOACs) Device Market, Segmentation By Disease , Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.4. Africa Direct Oral Anticoagulants (DOACs) Device Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Direct Oral Anticoagulants (DOACs) Device Market Competitive Landscape And Company Profiles

30.1. Direct Oral Anticoagulants (DOACs) Device Market Competitive Landscape
30.2. Direct Oral Anticoagulants (DOACs) Device Market Company Profiles
- 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.2. Roche Diagnostics Corporation Overview, Products and Services, Strategy and Financial Analysis
- 30.2.3. Bristol-Myers Squibb Company Overview, Products and Services, Strategy and Financial Analysis
- 30.2.4. Siemens Healthcare GmbH Overview, Products and Services, Strategy and Financial Analysis
- 30.2.5. Becton Dickinson And Company Overview, Products and Services, Strategy and Financial Analysis

31. Direct Oral Anticoagulants (DOACs) Device Market Other Major And Innovative Companies

31.1. Boehringer Ingelheim International GmbH
31.2. Teva Pharmaceutical Industries Limited
31.3. Daiichi Sankyo Co. Ltd
31.4. Sysmex Corporation
31.5. Dr. Reddy's Laboratories Limited
31.6. Werfen S.A.
31.7. Alembic Pharmaceuticals Limited
31.8. Diagnostica Stago SAS
31.9. Helena Laboratories Corporation
31.10. iLine Microsystems S.L.
31.11. Technoclone GmbH
31.12. Anthos Therapeutics Inc.
31.13. FLoBio LLC
31.14. Perosphere Technologies Inc.
31.15. DOASENSE GmbH

32. Global Direct Oral Anticoagulants (DOACs) Device Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Direct Oral Anticoagulants (DOACs) Device Market

34. Recent Developments In The Direct Oral Anticoagulants (DOACs) Device Market

35. Direct Oral Anticoagulants (DOACs) Device Market High Potential Countries, Segments and Strategies

35.1 Direct Oral Anticoagulants (DOACs) Device Market In 2029 - Countries Offering Most New Opportunities
35.2 Direct Oral Anticoagulants (DOACs) Device Market In 2029 - Segments Offering Most New Opportunities
35.3 Direct Oral Anticoagulants (DOACs) Device Market In 2029 - Growth Strategies
- 35.3.1 Market Trend Based Strategies
- 35.3.2 Competitor Strategies

36. Appendix

36.1. Abbreviations
36.2. Currencies
36.3. Historic And Forecast Inflation Rates
36.4. Research Inquiries
36.5. The Business Research Company
36.6. Copyright And Disclaimer